Gene Silencing
Antisense thioredoxin may stop tumor angiogenesis by altering HIF-1
Published in Gene Therapy Weekly, May 26th, 2005
According to a study from South Korea, "thioredoxin (Trx), a small redox protein, is overexpressed in a number of tumors, however, its roles in tumor cells were not defined well. To investigate the effect of Trx, we transfected Trx or antisense Trx vectors into HT1080 cells. Trx-overexpressed HT1080 cells induced migration of endothelial cells through Flt-1 vascular endothelial growth factor (VEGF) receptor type-1."
"However, the migration was reduced by overexpression of antisense-Trx. To understand the relationship between Trx and hypoxia-induced angiogenesis, we observed the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-05-26)
More Articles from Gene Therapy Weekly
- Cancer Therapy
Tumor vessel targeting by interferon gamma triggers antitumor activity - Gene Silencing
STAT3 knockdown shutters breast tumor formation in murine models - Liver Cancer
Antiangiogenic gene therapy treats tumors in hepatocellular carcinoma models - Neuroscience
Genetically modified olfactory-derived cells regenerate corticospinal axons - Oncology
The PDX-1 gene is an early marker for a variety of human cancers - Antileukemic
Third generation biphosphate YM529 antileukemic - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
